Drugs

Drug-Induced Liver Toxicity

Drugs sometimes cause serious injuries to the livers of patients, with loss of hepatic function leading to illness, disability, hospitalization, and even life threatening liver failure and death or need for liver transplantation. As our aging world population uses more and more drugs, as well as self-prescribed over-the-counter medications, so-called “dietary supplements,” special diets, alcohol, and is exposed also to environmental chemicals, chances of such injury are rising. In the United States, drug-induced liver injury (DILI) is now the leading cause of acute liver failure (ALF), exceeding all other causes combined [see below: recent graphic data from WM Lee and colleagues from the Acute Liver Failure Study Group, updated to include data through 2012].   


graph of etiology of acute liver failure in the U.S., January 2014


This website is intended to present up-to-date presentations and discussions on issues pertinent to DILI, as well as some background information from previous conferences. The site is sponsored by the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), together with the American Association for the Study of Liver Diseases disclaimer icon (AASLD), the Drug-Induced Liver Injury Network disclaimer icon (DILIN) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and Pharmaceutical Research and Manufacturers of America (PhRMA).

If you wish to use any of the material posted at this website, please request permission from any of the authors to do so, and please cite the source of the material giving credit to them.

Please send critique, comment, and suggestions for improvement of this website to John R. Senior, M.D. (john.senior@fda.hhs.gov) or Lana Pauls, M.P.H. (lana.pauls@fda.hhs.gov).
  

2014 Meeting

The March 19-20, 2014 program was co-sponsored by the FDA/CDER, the Critical Path Institute (C-Path), and the Pharmaceutical Research and Manufacturers of America (PhRMA).  The program was endorsed by the National Institutes of Health (NIH) drug-induced liver injury network (DILIN), and the American Association for the Study of Liver Diseases (AASLD).


Previous Meetings

 
Report serious adverse events to FDA's MedWatch, using the contact information below.

                       

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857

Page Last Updated: 10/22/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.